{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045310","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.321190+00:00","generated_at":"2026-05-22T07:35:07.567287+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ironwood Q1 net loss $37.4M; revenue down 45% YoY; raises adjusted EBITDA guidance to >$105M","bullets":["Total revenue of $41.1M vs $74.9M in Q1 2024, down 45% YoY.","GAAP net loss $37.4M ($0.23 loss per share) vs $4.2M loss a year ago.","Adjusted EBITDA guidance raised to >$105M for FY 2025; on track to meet full-year guidance.","LINZESS prescription demand grew 8% YoY in Q1 2025, in line with expectations.","Company is exploring strategic alternatives to maximize stockholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045310","json":"https://secwatch.observer/filing/0001104659-25-045310.json","markdown":"https://secwatch.observer/filing/0001104659-25-045310.md","text":"https://secwatch.observer/filing/0001104659-25-045310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/0001104659-25-045310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/tm2514185d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:35:07.567287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}